



**Post-doctoral Position available at CERVOxy group, ISTCT laboratory, GIP CYCERON, France**

---

**Position: Full time post-doctoral position**, fixed-term contract to begin before 01/04/2018

Duration: 2 years

Salary: Monthly net paid: around 2,100 €/month to be contracted with the CNRS.

Financing: French Institut National du Cancer (INCa)

Contact: Dr Samuel Valable

Application deadline 15 March 2018.

**Description of the position**

**Context:** One major feature of glioblastoma (GB) is their pronounced resistance to treatments namely radiation therapy (RT) and chemotherapy (CT) mainly associated with their hypoxic nature. A markedly poor independent prognostic factor is documented as an obstacle to the efficacy of conventional therapies. Therefore, this project aims at (i) alleviating tumor hypoxia to improve RT and (ii) radiosensitizing tumor cells as an attractive strategy to improve patient survival using nanosized microporous crystals.

**Objective:** He/she will be in charge of managing *in vitro* and *in vivo* experiments to analyze the potential of nanosize zeolites for treating brain tumors and/or improving existing treatments (CT, RT). He/she will also be in charge of the scientific dissemination around the project and will be involved in the general organization of the lab.

**Required qualification:** Knowledge in brain tumors, hypoxia, radiation therapy, *in vitro* models and *in vivo* models are required. Experience in *in vivo* imaging is also desired. Candidates who recently completed their graduate degree or those with 1-2 years of postdoctoral experience are encouraged to apply.

**Keywords:** Glioblastoma, hypoxia, nanoparticles, radiation therapy, preclinical approaches.

**Laboratory**

The CERVOxy team (ISTCT unit) is hosted by the GIP CYCERON in Caen. The CERVOxy team conducts research around hypoxia, vasculature and inflammation in a context of cerebral pathologies and more particularly high-grade brain tumors. The aim of the research is to identify new and relevant therapeutic targets and to validate these new therapies through biomedical imaging (MRI / PET) approaches from the basic scale to the clinical scale. Composed of researchers from different backgrounds, the team has a strong interaction with the CYCERON imaging platform (platform labelled IBISA) as well as the animal care facility of the University of Caen, CURB. The technologies used to develop these themes include cellular and molecular biology, physiology and integrated *in vivo* imaging. Along with the imaging facilities, CYCERON hosts a small animal dedicated Irradiator (XRad 225 Cx) funded by a PIA2 program Rec-Hadron.

**Contacts:**

CV, cover letter and letters of reference should be sent to:

Dr Samuel VALABLE: [samuel.valable@cnr.fr](mailto:samuel.valable@cnr.fr);

ISTCT Lab, CERVOxy group

GIP CYCERON, Bd Henri Becquerel, BP5229

F-14074 CAEN cedex, France

(33) 2 31 47 01 08

<http://www.istct.cyceron.fr>